Brain-computer interface (BCI) technology represents one of the most transformative frontiers in neuroscience and neurotechnology. BCI systems enable direct communication between the brain and external devices, with applications spanning medical therapeutics, cognitive augmentation, and neural prosthetics. For neurodegenerative disease research, BCI technology offers revolutionary possibilities for restoring function in patients with movement disorders, communication deficits, and sensory impairments["@braincomputer"].
This page provides comprehensive coverage of companies developing BCI technologies, including implantable neural interfaces, non-invasive EEG systems, and emerging therapeutic applications for neurological conditions.
The BCI market has experienced unprecedented growth since 2020, driven by:
Headquarters: Fremont, California, USA Status: Human clinical trials (PRIME Study)
Neuralink develops the N1 implant, a fully implantable, wireless brain-computer interface with 1,024+ electrodes. The company received FDA breakthrough device designation in 2020 and began human trials in 2023. Neuralink's technology targets movement restoration, vision prosthesis, and communication applications[@neuralink][@neuralinka].
See Neuralink for detailed coverage.
Headquarters: New York, New York, USA Ticker: Private Status: Clinical trials (COMMANDER Study)
Synchron developed the Stentrode, a minimally invasive neural interface that routes through the jugular vein to the motor [cortex](/brain-regions/cortex). Unlike traditional brain implants, Stentrode does not require open-brain surgery. The device received FDA breakthrough device designation in 2020 and is currently in human trials for patients with paralysis[@synchron].
See Synchron for detailed coverage.
Technology:
| Feature | Specification |
|---------|---------------|
| Implantation | Endovascular (jugular vein) |
| Electrodes | 16-channel stent-array |
| Data transmission | Wireless |
| Target | Motor cortex |
Headquarters: Salt Lake City, Utah, USA Status: Clinical (Longest-running BCI company)
Blackrock Neurotech has been developing neural interfaces since 2008 and holds the longest record of human BCI implantations. The Utah Array has been used in numerous research studies and early clinical applications[@blackrock].
Products:
| Product | Description | Status |
|---------|-------------|--------|
| Utah Array | Rigid microelectrode array | Clinical |
| NeuroPort | Integrated recording system | Commercial |
| Blackrock SIMS | Smart implant system | Development |
Headquarters: Los Angeles, California, USA Status: Preclinical
Paradromics is developing the Connexus Direct Data Interface, a high-bandwidth neural implant designed for communication restoration. The company focuses on patients with locked-in syndrome and severe paralysis[@paradromics].
Technical Specifications:
Headquarters: New York, New York, USA Status: Clinical
Precision Neuroscience developed the Layer 7 Cortical Interface, a thin-film electrode array that sits on the brain surface rather than penetrating tissue. This approach aims to reduce tissue damage while maintaining high signal quality[@precision].
Headquarters: San Francisco, California, USA Status: Commercial
EMOTIV develops consumer and research-grade EEG headsets for brain-computer interface applications. Their technology enables thought-controlled interactions with computers and applications^8].
See EMOTIV for detailed coverage.
Headquarters: Graz, Austria Status: Commercial
g.tec is a leading provider of high-performance EEG systems for research, clinical, and BCI applications. The company offers both hardware and software solutions for neural signal acquisition and processing^9].
See g.tec for detailed coverage.
Headquarters: Toronto, Ontario, Canada Status: Consumer commercial
InteraXON (Muse) develops consumer EEG headbands for meditation and brain training applications. While primarily focused on wellness, their technology represents accessible BCI for consumers^10].
Headquarters: Paris, France Status: Commercial (Acquired by Snap Inc.)
NextMind developed a non-invasive EEG-based brain-sensing device for visual perception decoding. The company was acquired by Snap Inc. in 2021^11].
BCI technology offers several therapeutic applications for neurodegenerative :
| Application | Technology | Target Condition |
|-------------|------------|------------------|
| Deep brain stimulation | Invasive electrodes | PD, AD |
| Motor restoration | Neural prosthetics | PD, ALS |
| Cognitive monitoring | EEG | AD progression |
| Communication | BCI | ALS, locked-in |
| Memory enhancement | Neural interfaces | AD |
Several BCI companies specifically focus on neurodegenerative disease applications:
| Company | Device | Indication | Stage |
|---------|--------|------------|-------|
| Neuralink | N1 | Paralysis | Phase 1 |
| Synchron | Stentrode | Paralysis | Phase 1 |
| Blackrock | Utah Array | Research | Clinical |
| Precision Neuroscience | Layer 7 | Epilepsy | Phase 1 |
| Company | Funding | Year | Investors |
|---------|---------|------|-----------|
| Neuralink | $680M | 2024 | Founders Fund, GV |
| Synchron | $100M | 2022 | Khosla, Andreessen |
| Paradromics | $72M | 2023 | ARCH, Prime |
| Precision Neuroscience | $93M | 2023 | Andreessen, ...
The BCI market is projected to reach $7-12 billion by 2030, driven by:
| Company | Modality | Invasiveness | Channels | Status |
|---------|----------|---------------|----------|--------|
| Neuralink | ECoG/Intracortical | Fully invasive | 1,024+ | Human trials |
| Synchron | Endovascular | Minimally invasive | 16 | Human trials |
| Blackrock | Intracortical | Invasive | 100+ | Clinical |
| Paradromics | Intracortical | Invasive | 1,000+ | Preclinical |
| Precision Neuroscience | ECoG | Surface | 1,024+ | Human trials |
| EMOTIV | EEG | Non-invasive | 14-32 | Commercial |
| g.tec | EEG | Non-invasive | 64-256 | Commercial |
BCI devices navigate FDA's Class III medical device pathway, typically requiring: